A new paper by the America First Policy Institute, a think tank with close ties to the Trump administration, has revived the debate over global drug pricing.
The paper points out that patients in the United States tend to pay considerably more for brand-name prescription drugs than those in most other wealthy nations. The think tank argues that the Trump administration should find ways to force other countries to pay more for drugs — and thus pick up a more equitable share of the cost of developing new medicines.
The intent is right. Unfortunately, the paper’s methods for achieving it would slow global innovation — and fail to compel other countries to pay more for drugs.
Read more at Newsmax© 2025 Newsmax. All rights reserved.
